On March 20, the patent on Semaglutide, the molecule used in GLP-1 drugs like Ozempic and Wegovy expired in India, allowing the release of cheaper alternatives. According to an article by the BBC, this could cause prices to drop rapidly and increase access for patients across India, and eventually globally.
Wegovy is a GLP-1 that is commonly used for weight loss, Photo: Arianna Buonocore. Senior Lecturer at Curtin Law School, Dr Nikolas Koutras…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.